Unibest
← Back to patent-cliff list

DM-5167

Tier C — Watch / trade

DM-5167

-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:PARP1

Indications (approved):Solid tumour, Breast cancer, 三阴性乳腺癌

Regional status

US
-
EU
-
China
-
Japan
-

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of DM-5167?

Approved indications include: Solid tumour, Breast cancer, 三阴性乳腺癌.

When does the DM-5167 patent expire?

No public expiry year is available for DM-5167 yet; this page updates once verified.

How do I get a quote for DM-5167 intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-02